Skip to main content

Table 1 Patient characteristics at the time of [68Ga]Ga-PSMA-11 scan

From: Gallium-68 prostate-specific membrane antigen ([68Ga]Ga-PSMA-11) PET for imaging of thyroid cancer: a feasibility study

Patient # Age Sex Thyro-globulin (ng/mL); Ab +/− TSH (mIU/ L) Tumor type Years since diagnosis Treatment history Years Since RAI; EBRT I-123/131 uptake on most recent scan? Months to PSMA PET
1 78 M 17; − 0.36 PTC 14 S, RAIx1, EBRT 6; 1 No 3.0
2 58 F 520.2; + 0.01 HCC 5 S, RAIx2, EBRT 3; 1 No 1.8
3 80 M 22.0; − 0.11 PDPTC 28 S n/a; n/a No 2.4
4 79 M 245.1; + 2.7 ATC < 1 S n/a; n/a Unknown 0.4
5 72 F 1771.0; − n/a FTC 5 S, RAIx2 4; n/a No 1.8
6 65 F 2125.8;− 0.01 PDPTC 3 S, EBRT n/a; 1 No 3.0
7 66 F 7.3; − 0.11 PTC 3 S, RAIx1, EBRT 3; 3 No 5.3
8 46 F 0.1; − 12.1 ATC < 1 S, RAIx1 0.5; n/a No 1.2
9 62 M 0.1; +  0.37 PTC 2 S, RAIx2 1; n/a No 0.7
10 47 F 20,540.0; − 0.01 FTC < 1 S n/a; n/a Yes* 11.4
11 54 M 15.6; − 0.13 HCC 8 S, RAIx3, EBRT 4; 2 Unknown 1.5
  1. Time to PSMA PET: months from most recent 2-[18F]FDG PET or [123I]Iodide/[131I]Iodide scan to [68Ga]Ga-PSMA-11 PET
  2. Ab anti-thyroglobulin antibodies, TSH thyroid stimulating hormone, PTC papillary thyroid carcinoma, HCC Hurthle cell carcinoma, PDPTC poorly differentiated papillary thyroid carcinoma, ATC anaplastic thyroid carcinoma, FTC follicular thyroid carcinoma, S surgery, RAI radioactive iodine therapy, EBRT external beam radiation therapy, Chemo chemotherapy
  3. *Patient 10 was planned for RAI which was performed approximately 1 month after imaging workup (including PSMA PET)